Pak actors, singers are artists; don't treat them like terrorists: Salman Khan

Bengaluru, May 29: Karnataka reported 248 new cases of coronavirus on Friday, and with that, the state tally surged to 2,781. 

A 50-year-old woman, resident of Chikkaballapura district, succumbed to the infection on Friday. She was admitted to a private hospital on May 24 following acute kidney injury and pneumonia. As her condition deterorted, she was shifted to a designated hospital in Bengaluru Urban on May 28, where she tested COVID-19 positive.

Out of the 248 cases, only 16 persons have contracted the virus inside the state. The remaining are the people who have returned from Maharashtra, Delhi, Andhra Pradesh, Tamil Nadu and Ireland.

The maximum number of people, who tested positive for COVID-19, have returned from Maharashtra. Most of these people are residents of Udupi, Kalaburagi, Yadagiri and Raichuru.

Besides, five people have a travel history to Delhi, while one person each has tested positive on returning from Andhra Pradesh, Tamil Nadu, Rajasthan and Ireland.

Fifteen people have tested positive within the state and have been infected by persons who had previously tested positive or have a history of Influenza-like Illness and Severe Acute Respiratory Illness.

Out of all the cases, 10 have been reported in Bengaluru Urban while one has come up in Bengaluru Rural.

Meanwhile, on Thursday, the Karnataka government asked the Civil Aviation Ministry to reduce the number of flights coming in the state from the five worst-hit states -- Maharashtra, Tamil Nadu, Gujarat, Madhya Pradesh and Rajasthan.

"Karnataka has appealed to the Civil Aviation Ministry to take steps to lessen the air traffic to the state, with the sacred intention that there may not be adequate quarantine facilities if there is a huge turnout in a short span of time," state Law and Parliamentary Affairs Minister J.C. Madhuswamy explained.

Bengaluru, Mar 30: Coffee Day Enterprises Ltd (CDEL) has received the first tranche of Rs 2,000 crore following disinvestment of Global Village Techparks to repay debts following the death of its founder V G Siddhartha.
In August last year, CDEL executed definitive agreements with entities belonging to Blackstone Group and Salarpuria Sattva Group for investment in GV Techparks, a wholly-owned subsidiary of group company Tanglin Development Ltd (TDL), at an enterprise value of Rs 2,700 crore.
The balance amount is expected to be received after the receipt of few statutory approvals, CDEL said in a statement.
"Out of the money received in first tranche, the company has paid off its debts in full including principal and interest amounting to Rs 1,644 crore to the lenders despite difficult economic conditions," it said.
Post this payment, the consolidated debt of the company and its subsidiaries stands at Rs 3,200 crore as on March 27. This includes debt of Rs 1,400 crore of its subsidiary Sical Logistics Ltd where disinvestment process is in progress.
"The company and subsidiaries have repaid around Rs 4,000 crore to the lenders since the beginning of this financial year," CDEL said.
"With the continuous support of stakeholders of the company, the current management is working to ensure better liquidity and operational efficiency. The company is confident of the future ahead despite various challenges," it added.
The company has been in rough waters after its founder V G Siddhartha took his own life as debt strains began to emerge in his company. Since his death in July last year, CDEL has been trying to divest its assets to pare debts.
On July 30, 2019, CDEL informed stock exchanges about Siddhartha's disappearance. In a letter that was purportedly written by him, the Cafe Coffee Day founder said: "I could not take any more pressure from one of the private equity partners forcing me to buy back shares."

Bengaluru, Mar 27: Oncologist Dr. Vishal Rao, HCG Hospital Bengaluru on Friday said that human body cells release interferon chemical to kill viruses but it cannot be released by cells in the case of COVID-19 cases, leading to weak immune system. However, a therapy of specific concoction could be useful in treating COVID-19 patients.

"We got hold of some preprint suggesting that interferon is effective in COVID19," said Rao.

Speaking to news agency, he continued saying "When we withdraw blood for regular check-ups, we get buffy coat which can be used to take out cells and form interferon. These two chemicals and some other cytokines, in a specific concoction, could be potentially very useful in treating COVID-19 patients."

Rao said that they have built a concoction of cytokines which can be injected to reactivate immune system in COVID-19 patients.

"We are in a very initial stage and hope to be ready with its first set by this weekend. We have applied to the governement for an expedited review. We have also presented this before the state government" said Rao.

"We have a team of infection specialist, ICU team and other...all of us have worked together to build something that we believe. We want to serve the society at this hour of need," he added.

Dr Rao clarified that this is not a vaccine and this particular interferon therapy does not help to prevent the infection of COVID-19. However, this is focused and targeted towards COVID-19 positive patients or those who have just incubated the virus.

"We believe that in early stages as well as the patients who have just incubated, this particular therapy of interferon gama and other concoction of cytokines could be an effective method. In the late stages we are looking at specific dosage of the cells which are our own body cells which can actually be affective and could also be of use for the ventilator patients," he added.

Meanwhile, Dr Gururaj, Immunologist and Scientist told ANI that they are trying to cover two aspects, one is the early stage patients where they are trying to improve their immune systems.

"As Dr Vishal said, we are trying to see whether we can use the cytokines from our own immune cells which is a natural process but it is hampered in infected patients," said Dr Gururaj.

"In the last phase we are using cells which are used from the bone marrow of the patient or donors. We can use those cells to reduce the inflation and so called cytokines release syndrome which is basically the inflammatory response of the body," he added.